Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i - Nature Medicine

Australia News News

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i - Nature Medicine
Australia Latest News,Australia Headlines
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 58 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 53%

Analyses from the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in patients with metastatic melanoma demonstrate high response rates and uncover molecular correlates of long-term treatment benefit. Trial led by AACR23 speaker Reinhard Dummer

R.D. reports intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme , Bristol Myers Squibb , Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron and Alligator outside the submitted work. C.L.

Extended Data Fig. 2 Best percent change from baseline in sum of diameters by local investigator review . A total of 33 patients experienced a reduction in the size of the target lesion. One patient with SD had a best percent change of 0% in the target lesion. Best percent change in the target lesion was not available for 1 patient with PD. Best percent change in target lesion could not be calculated for 1 additional patient as best overall response was unknown. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Extended Data Fig. 3 Time-to-event analyses, including DOR, PFS, and OS, in patients enrolled in parts 1 and 2 of COMBI-i . 12- and 24-month DOR rates were 80% and 53% ; 12- and 24-month PFS rates were 67% and 41% ; 12- and 24-month OS rates were 86% and 74% . DOR, duration of response; PFS, progression-free survival; NE, not estimable; OS, overall survival.Baseline T-cell–inflamed GES levels and TMB in samples from patients with and without a CR. For T-cell–inflamed GES: n=27 independent tumor biopsy specimens . For TMB: n=24 independent tumor biopsy specimens .

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureMedicine /  🏆 451. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Steven Spielberg, David Zaslav & Paul Thomas Anderson Talk Urgency Of Film Preservation And Warners Bros. Commitment At TCM Classic Festival Opening NightSteven Spielberg, David Zaslav & Paul Thomas Anderson Talk Urgency Of Film Preservation And Warners Bros. Commitment At TCM Classic Festival Opening NightWarner Bros. Discovery CEO and President David Zaslav joined Steven Spielberg and Paul Thomas Anderson to tout another area close to his heart of the studio, the importance of restoring and preserving Warner Bros. rich legacy of film classics
Read more »

Report: Police agencies exceeded overtime budgets countywide as a result of staffing challengesReport: Police agencies exceeded overtime budgets countywide as a result of staffing challengesPolice departments and the Sheriff's Department exceed their overtime budgets by $35.4 million combined, report says
Read more »

Hyundai Motor Plug-In Car Sales Doubled In March 2023Hyundai Motor Plug-In Car Sales Doubled In March 2023Last month, the combined wholesale shipments (closely related to production) of Hyundai and Genesis plug-in cars amounted to *34,125 (up 110% year-over-year).
Read more »

mRNA cancer vaccine an 'exciting' advance in reducing risk of melanoma relapse, trial showsmRNA cancer vaccine an 'exciting' advance in reducing risk of melanoma relapse, trial showsExperts called the results of the combined immunotherapy with personalized mRNA technology an exciting advance in the field of cancer vaccines.
Read more »

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Nature MedicineSotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial - Nature MedicineIn a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.
Read more »



Render Time: 2025-02-28 00:15:59